A plasma metabolomic model obtained by means of untargeted 1 H nuclear magnetic resonance, to which taurine, choline, methylamine, total glutathione, trimethylamine N-oxide, lactate, lysine, isoleucine, total fatty acids and unsaturated fatty acids contributed, was validated for the prediction of first episodes of cytomegalovirus (CMV) DNAaemia in a cohort of 79 allogeneic stem haematopoietic stem cell transplant (allo-HSCT) recipients. The predictive success rate was nearly 65 % for patients at both low and high risk of CMV-related complications according to their baseline characteristics. Plasma metabolomics profiling shortly after engraftment (day 21 after transplantation) allowed the anticipation of the occurrence of CMV DNAaemia in 71 % of patients. Plasma metabolomics analyses may be ancillary for identifying allo-HSCT patients at the highest risk of CMV DNAaemia who may benefit from early targeted antiviral prophylaxis.
Cytomegalovirus (CMV) DNAaemia occurs frequently in allogeneic haematopoietic stem cell transplant recipients and may lead to end-organ disease if preventative measures are not implemented in a timely manner (i.e. administration of preemptive antiviral therapy) [1] . Moreover, it has been suggested that even when it occurs at a low level, CMV DNAaemia may have a deleterious impact on patient survival [2] , although the extent of this remains controversial [3] . If the latter assumption holds true, prediction of the occurrence of viraemia, quickly followed by the inception of antiviral prophylaxis, would likely result in tangible benefits to patients. The advent of novel antivirals showing excellent efficacy against CMV and a good safety profile, such as letermovir [4] , makes this targeted prophylaxis strategy an appealing approach. Unfortunately, baseline transplant factors are insufficiently precise to identify patients at the highest risk of CMV DNAaemia [1] .
Metabolomic analysis aims at identifying and quantifying small molecule metabolic products of a biological system (cell, tissue, organ, biological fluid, or organism) at a given time point by means of targeted or untargeted nuclear magnetic resonance (NMR) or mass spectrometry methods [5] . This type of molecular analysis is increasingly being viewed as a potential tool for optimizing the management of infectious diseases caused by viruses [6] [7] [8] [9] . In this context, we previously identified a plasma metabolomic signature by means of 1 H nuclear magnetic resonance spectroscopy, which may serve this purpose [10] . Up to 10 metabolites were found to contribute to this predictive chemometric model, including taurine, choline, methylamine, total glutathione (GsX), trimethylamine N-oxide (TMAO), lactate, and total and unsaturated fatty acids, which were upregulated in patients who eventually developed CMV DNAaemia, and lysine and isoleucine, which were found to be downregulated in these patients. This metabolomic profile was interpreted as reflecting a systemic 'hyperinflammatory' state (increase in methyalmines and lactate concentrations), coupled with ongoing compensatory mechanisms mediated by antioxidants such as total GsX and taurine [10] , and was pathogenetically linked to the occurrence of CMV DNAaemia by virtue of the well-known triggering effect of inflammation on CMV reactivation in organ and tissues [11] . For the present study we built a new independent validation cohort to test this plasma metabolomics model.
The current cohort consisted of 79 non-consecutive adult patients who underwent T-cell replete Allo-HSCT for haematological disorders at the Haematology Unit of the Hospital Clínico Universitario (HCU) of Valencia between June 2013 and August 2015. The median age of patients was 54 years (range, 20 to 70 years). The patients' relevant clinical and demographic data are shown in Table 1 . No exclusion criteria other than a lack of available plasma specimens for metabolomics profiling was applied. The study period comprised the first 100 days after allo-HSCT and only initial (first) episodes of CMV DNAaemia were considered for the analyses described herein.
Monitoring of plasma CMV DNAaemia was performed by real-time PCR (Abbott RealTime CMV, Abbott Molecular, Des Plaines, IL, USA) as previously described [12] . The limit of detection and quantitation of this assay is approximately 31 IU ml À1 (20 copies ml
À1
) [13] . Surveillance for CMV DNA detection in plasma was conducted at least once a week within the study period.
Of the 79 patients, 50 (63.2 %) had a first episode of CMV DNAaemia at a median 39 days after allo-HSCT (range, 10 to 99 days). The median initial CMV DNA load was 102 IU ml À1 (range, 30-177 086 IU ml
) and the median CMV DNA peak load within episodes was 1803 IU ml À1 (range, 75-4 159 486 IU ml À1 ). The remaining 29 patients had no documented CMV DNAaemia within the study period. Preemptive antiviral treatment was given to 25 patients (50 %). One patient developed CMV end-organ disease (gastrointestinal disease). The incidence of bacterial infections of any origin and severe acute graft-versus-host disease requiring the administration of corticosteroids at high doses within the study period was balanced between patients with and without CMV DNAaemia (not shown). This is of relevance because of the potential effect of these two events on the composition of the plasma metabolome [14] .
A total of 135 plasma samples (test specimens) were available from patients who developed CMV DNAaemia (median, two specimens/patient; range, one to eight/ patient). These specimens were collected at approximately 1-week intervals, and were drawn prior to the documentation of this event. Most specimens (~90 %) were obtained through day 40 after transplantation. In turn, 92 samples drawn within a comparable time frame after allo-HSCT were available from patients who had no CMV DNAaemia within the study period (control specimens).
Plasma processing for metabolomics profiling has previously been described in detail [10] . Briefly, samples that had been cryopreserved at À20 C (and never thawed before) were retrieved immediately prior to processing. Fifty microlitres of D 2 O were added to 500 µl of plasma and an aliquot of 500 µl was taken and placed in a 5 mm NMR tube. The 1 H-NMR spectra were recorded in a Bruker Avance DRX 600 spectrometer (Bruker GmbH, Rheinstetten, Germany). A [5] . Signals belonging to the metabolites contributing the most to VIP scores in the models were integrated and quantified using semi-automated inhouse MATLAB 7.4 (The Mathworks, Inc.) peak-fitting Relative changes in the concentration of metabolites with the PLS-DA plasma metabolomics model VIP scores !1 between samples from patients subsequently developing CMV DNAaemia and specimens from patients with no documented CMV DNAaemia within the study period. The changes were calculated as the differences between the average values for test specimens and control samples normalized to the average values for control specimens. Positive and negative values on the x-axis mean that the average concentration for a given metabolite in the test group is higher or lower, respectively, than in the control group. The represented numerical values Â100 correspond to the percentage increase or decrease for each metabolite. The statistical significance of the differences at the 0.05 level was tested using the Anova two-tailed test with Bonferroni correction for multiple testing (*P-value <0.05; **P-value <0.01). FA, fatty acids; GsX, total gluthatione; TMAO, trimethylamine N-oxide; UFA, unsaturated fatty acids.
routines. These fitting routines were based on LevenbergMarquardt optimization procedures. The target function for optimization included experimental spectra measured for standard solutions of selected metabolites with complex multiplet patterns and theoretically generated Lorentzian-shape signals for metabolites with simpler spectral patterns. The metabolic levels were expressed as total relative metabolic content (calculated as the integral of the selected metabolite divided by the sum of all integrals in the spectra). The statistical significance of the differences at the 0.05 level was tested using the Anova two-way test with Bonferroni correction for multiple testing.
As shown in Fig. 1(a) , the projection of this validation cohort over the scores plot diagram of our previous metabolomics PLS-DA training model [10] showed good profile agreement, with only three samples being out of the 95 % confidence range. The trends of 8 out of the 10 metabolites contributing to the training model (VIP scores !1), including taurine, choline, methylamine, lactate, and total and unsaturated fatty acids, all of which upregulated in plasma specimens from patients subsequently developing CMV DNAaemia, and lysine and isoleucine, which were found to be downregulated, were reproduced in the validation cohort ( Fig. 1b and Table S1 , available in the online version of this article), although only choline, methylamine and lactate were present in concentrations that differed significantly between the test and control specimens. In contrast to our previous findings, no differences were observed between test and control samples of the remaining two metabolites, GsX and TMAO. Despite these dissimilarities, the prediction success rate of the model for CMV DNAaemia was 64 % for both samples (87 out of 135 plasma specimens from patients who eventually had DNAaemia were correctly classified; a median of 2 specimens; range, 0-4/patient) and patients (32 out of 50 patients with 1 or more specimens fitting the metabolomics model were correctly categorized).
The overall classification accuracy of the PLS-DA model in cross-validation technical replicates was 73 % in the training cohort [10] . Differences in baseline and post-transplant patient characteristics, as well as subtle dissimilarities in sampling times between the training and validation cohorts, may account for the small decrease in the discriminative ability of the model.
We next assessed how effectively the model predicted the occurrence of CMV DNAaemia in patients categorized as either high or low risk for this event (and for end-organ disease) according to their pre-transplant characteristics [1] . Patients meeting one or more of the following conditions were deemed to be high risk: receipt of umbilical cord blood or bone marrow allograft; HLA-mismatched donor (including haploidentical donor); D-/R+CMV serological constellation. Low-risk patients were those not meeting any of the above conditions.
A total of 59 high-risk patients were included in the validation cohort, of whom 39 had CMV DNAaemia. A total of 173 blood samples were available from these patients, of which 106 belonged to patients who went on to develop CMV DNAaemia. The model was able to correctly classify 65 % of plasma specimens from these patients (69 out of 106 samples; a median of 2 specimens; range, 0-4/patient) and precisely categorized 64 % of patients (12 out of 20). The trends and relative concentration of most metabolites contributing to the model in test and control samples for this subset of allo-HSCT recipients ( Fig. 2a and Table S2) virtually overlapped with those in the training cohort [10] . Only isoleucine showed an opposite trend.
In all, the cohort included 20 low-risk patients, of whom 11 eventually developed CMV DNAaemia. A total of 54 plasma samples were available from this subset of patients, of which 29 were obtained from those who had subsequently CMV DNAaemia. The prediction success rate of the metabolomics model was 64 % (18 out of 29 samples correctly categorized; median of 2 specimens; range, 0-3/patient; 7 out of 11 patients correctly categorized). The relative concentration of the metabolites contributing to the model in the test and control specimens was slightly different from that in the training cohort [10] (Fig. 2b and Table S3 ). In particular, GsX and taurine showed an opposite trend.
In our previous study [10] we observed that the maximal prediction rate of the model was achieved when analysing specimens drawn at around 3 weeks after allo-HSCT. Specimens obtained at a median of 21 days after allo-HSCT (range, 18 to 29 days) were available from 77 patients in this validation cohort, of whom 38 eventually developed CMV DNAaemia. The metabolomics model correctly predicted the occurrence of CMV DNAaemia in 27 out of 38 patients (71 %). The relative concentration of metabolites in the test and control samples ( Fig. 2c and Table S4 ) mirrored those in the training cohort, but the differences in certain components, such as GsX, TMAO, lactate and lysine, lost (although they approached) statistical significance.
Overall, it could be inferred from the above data that subtle and even remarkable differences in the trends or concentration of certain metabolites contributing to the model between the training and validation cohorts had only a minimal impact on its predictive ability. This is because the strength of this chemometric approach lies in the metabolomics profile itself, which is based on a combination of small metabolome variations, rather than the concentrations of individual metabolites [10] The current study confirms the utility of plasma metabolomics profiling for predicting first episodes of CMV DNAaemia in allo-HSCT recipients, as anticipated in our earlier study [10] . Of particular clinical interest is the predictive ability of the model when using a single plasma specimen drawn shortly after engraftment (day 21), as the majority of first CMV DNAaemia episodes occur at later times [1] . A novel observation made herein was the consistency of the discriminative ability of the model across subsets of patients at different risk of CMV-related complications, which minimizes the potential impact of cohort heterogeneity on the validity of the results.
The predictive ability of the model was nearly 70 % at best (single specimen obtained shortly after engraftment), meaning that the information provided by this biological approach would only be ancillary for the guidance of targeted antiviral prophylaxis. Perhaps a risk score could be developed to anticipate CMV DNAaemia that would integrate data obtained by plasma metabolomics with data obtained using other complementary biological approaches, such as CMV-specific T-cell monitoring and host genome analyses [1] , as well as information derived from baseline patient characteristics. Work to this end is currently underway. 
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